Credit Suisse released a research report that maintained Alibaba Health Information Technology's 00241 "outperform" rating, with a lower-than-expected net loss in the first half, cut revenue growth and gross profit margin, and lowered the target price from HK $15 to HK $11, Zhitong Financial APP learned.
According to the report, the management directs that revenue will grow by about 30% in the 2022-24 fiscal year, and gross revenue will be stable and profitable. Exploration of new businesses, such as proprietary pharmacies and personalized insurance, is under way. The bank does not expect to launch an online prescription drug sales policy this year, but the policy could affect revenue growth by several percentage points.